Nab-Paclitaxel

Overview

Nab-paclitaxel (brand name Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule-stabilizing taxane chemotherapy agent. By conjugating paclitaxel to human serum albumin nanoparticles, the formulation eliminates the need for the solvent Cremophor EL used in conventional paclitaxel, substantially reducing hypersensitivity reactions and enabling higher tolerable doses. The albumin carrier exploits endogenous albumin transport pathways — including receptor-mediated transcytosis via SPARC (secreted protein, acidic and rich in cysteine) and gp60 — to facilitate preferential accumulation in tumor tissue, thereby enhancing intratumoral drug delivery relative to solvent-based paclitaxel. Once inside the cell, nab-paclitaxel exerts its cytotoxic effect by stabilizing polymerized microtubules, preventing mitotic spindle disassembly and arresting cell division at the G2/M phase, ultimately triggering apoptosis.

Nab-paclitaxel is approved for multiple solid tumor indications, including metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with carboplatin, and metastatic pancreatic ductal adenocarcinoma in combination with gemcitabine. Its favorable pharmacokinetic profile, including higher maximum tolerated doses and greater tissue penetration, has made it an attractive backbone for combination regimens with targeted agents, antiangiogenics such as bevacizumab, and immune checkpoint inhibitors such as atezolizumab and durvalumab. Ongoing investigation continues to expand its role across a broad spectrum of malignancies, with particular focus on exploiting interactions between chemotherapy-induced immunogenic cell death and the tumor immune microenvironment.

Focus of Latest Publications

Recent clinical research has positioned nab-paclitaxel as a central chemotherapy partner in combination immunotherapy and targeted therapy regimens across multiple cancer types, reflecting both its established cytotoxic efficacy and its putative immunomodulatory properties.

Pancreatic Adenocarcinoma In advanced pancreatic ductal adenocarcinoma, a 2026 prospective cohort study (PMID 42216989) examining modified GTX as second-line therapy highlighted that no universally accepted second-line chemotherapy regimen exists following progression on FOLFIRINOX or the gemcitabine/nab-paclitaxel (Gemzar/Abraxane) combination, underscoring the continued relevance of nab-paclitaxel as a first-line standard against which second-line strategies are benchmarked. This context reflects the entrenched role of gemcitabine plus nab-paclitaxel as a foundational regimen in this disease setting and the unmet need for subsequent-line options.

Triple-Negative breast cancer Nab-paclitaxel has emerged as a key chemotherapy component in immunotherapy combinations for metastatic triple-negative breast cancer (mTNBC). The randomized, multicenter phase II INDUCE trial (JBCRG-M10; PMID 42128502) is investigating whether adding bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab plus nab-paclitaxel can overcome vascular endothelial growth factor (VEGF)-associated resistance mechanisms that limit the immune-mediated antitumor efficacy of atezolizumab and nab-paclitaxel in patients with PD-L1-positive mTNBC. The rationale centers on growth factors such as TGF-β1 and VEGF suppressing immune infiltration; antiangiogenic induction with bevacizumab is hypothesized to normalize tumor vasculature and enhance the subsequent immune response. In the neoadjuvant setting, the GeparNuevo trial (PMID 42008768) enrolled 174 patients with early TNBC randomized to durvalumab or placebo concurrently with weekly nab-paclitaxel, followed by dose-dense epirubicin and cyclophosphamide. Long-term analysis of this trial has provided important data on the durability of pathological complete response benefit conferred by checkpoint inhibition combined with nab-paclitaxel, with stromal tumor-infiltrating lymphocytes serving as a key correlative biomarker of immune engagement.

Non-Small Cell lung cancer Two recent studies have examined nab-paclitaxel in the perioperative and neoadjuvant NSCLC setting. An exploratory phase II trial (PMID 42114951) evaluated a four-cycle perioperative regimen combining serplulimab, a PD-1 inhibitor, with a taxane — either paclitaxel or nab-paclitaxel — and carboplatin in patients with resectable stage II–IIIA squamous NSCLC, assessing feasibility, efficacy, and biomarker correlates of response. A separate open-label, single-arm, prospective monocentric phase II trial (PMID 42003237) evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin and nab-paclitaxel in resectable non-squamous NSCLC, demonstrating the broad applicability of nab-paclitaxel-based immunochemotherapy across NSCLC histological subtypes. Together, these studies situate nab-paclitaxel as a preferred taxane partner for perioperative checkpoint blockade in resectable NSCLC.

Head and Neck Squamous Cell Carcinoma A phase 1b study (PMID 41956545) investigated a novel combination of ABBV-368 (an OX40 agonist), the toll-like receptor 9 agonist tilsotolimod, the PD-1 inhibitor budigalimab, and nab-paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The inclusion of nab-paclitaxel in this multi-agent immunostimulatory backbone reflects the hypothesis that chemotherapy-mediated tumor antigen release can synergize with innate immune activation (via TLR9 agonism) and adaptive checkpoint inhibitor to produce durable antitumor responses in a historically treatment-refractory setting.

Biliary Tract Cancer In advanced biliary tract cancer (BTC), a study using FDG PET/CT (PMID 41627846) evaluated the prognostic value of metabolic imaging parameters in patients receiving gemcitabine, cisplatin, and nab-paclitaxel (Gem/Cis/Nab-P). Although a phase 3 trial had not demonstrated an overall survival benefit for the triplet regimen across the unselected BTC population, the study identified favorable outcomes in specific subgroups — particularly those with locally advanced disease or gallbladder carcinoma — underscoring the value of patient selection and imaging biomarkers in optimizing nab-paclitaxel-based triplet therapy.

Key Publications

Jun Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026, PMID 42008768): "Hundred and seventy-four patients were randomly assigned to receive durvalumab or placebo concurrently with nab-paclitaxel once per week and followed by dose-dense epirubicin and cyclophosphamide."
Jun Efficacy and Safety of Modified GTX as Second-Line Therapy in Advanced Pancreatic Adenocarcinoma: A Prospective Cohort Study. (Journal of gastrointestinal cancer, 2026, PMID 42216989): "Advanced pancreatic adenocarcinoma lacks a universally accepted second-line chemotherapy regimen following progression on FOLFIRINOX or Gemzar/Abraxane."
May Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). (BMJ open, 2026, PMID 42128502): "Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel in patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel."
May Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis. (Journal for immunotherapy of cancer, 2026, PMID 42114951): "This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC."
Apr Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial. (International journal of cancer, 2026, PMID 42003237): "This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with resectable non-squamous non-small cell lung cancer."
Apr Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma. (Journal for immunotherapy of cancer, 2026, PMID 41956545): "Here, we investigate a treatment strategy with ABBV-368 combined with the investigational toll-like receptor 9 agonist tilsotolimod, the programmed cell death 1 inhibitor budigalimab, and nab-paclitaxel."
Apr Prognostic Value of FDG PET/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel. (Clinical nuclear medicine, 2026, PMID 41627846): "Although a phase 3 trial did not demonstrate a survival benefit for gemcitabine, cisplatin, and nab-paclitaxel (Gem/Cis/Nab-P) in advanced biliary tract cancer (BTC), favorable outcomes were observed in specific patient subgroups, notably those with locally advanced disease or gallbladder carcinoma (GBC)."